The negative prognostic role of LKB1 inactivation was confirmed in a large-scale, real-world, retrospective study conducted in 2407 patients with advanced NSCLC, which showed that patients with LKB1-mutated tumors (13.6% of the whole population) have worse PFS and OS when treated with either chemotherapy or immunotherapy, in both first- and in second-line settings [62]. This evidence concerns the gene STK11 and non-small cell lung carcinoma.